{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:39:49Z","timestamp":1787013589078,"version":"build-2736575974"},"reference-count":24,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T00:00:00Z","timestamp":1539129600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    A phase 3, multicenter, open\u2010label, 52\u2010week study investigated the efficacy and safety of adalimumab 80\u00a0mg at week 0 followed by adalimumab 40\u00a0mg every other week (option to escalate to 80\u00a0mg when necessary) in Japanese patients with generalized pustular psoriasis (GPP). Adults (aged 15\u201375\u00a0years) with GPP, total skin score (overall erythema area, erythema area with pustules, and edema area) of 3 or more, and erythema with pustules (skin score, \u22651) based on the 2014 Japanese Dermatological Association severity index of GPP were enrolled. The primary efficacy end\u2010point was clinical response at week 16 (non\u2010responder imputation), defined as achieving remission (total skin score, 0) or improvement from baseline (reduction of \u22651 point from a baseline total skin score of 3 or \u22652 points from a baseline total skin score of \u22654). Of 10 enrolled patients (mean disease duration, 10.6\u00a0years), seven patients, including three with the dose escalated to 80\u00a0mg every other week before week 15, achieved clinical response at week 16, and five achieved clinical response at week 52. Mean change from baseline total GPP score was \u22124.6 at week 16 (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a08) and \u22126.0 at week 52 (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a05); change in total skin score was \u22123.1 (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a08) and \u22124.2 (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a05), respectively. Nine patients experienced one or more adverse events and three experienced serious adverse events. The most common adverse events were nasopharyngitis, pruritus and hypoalbuminemia. In conclusion, adalimumab was effective and well tolerated for up to 52\u00a0weeks in the treatment of Japanese patients with GPP.\n                  <\/jats:p>","DOI":"10.1111\/1346-8138.14664","type":"journal-article","created":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T05:02:31Z","timestamp":1539147751000},"page":"1371-1380","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Adalimumab treatment in Japanese patients with generalized pustular psoriasis: Results of an open\u2010label phase 3 study"],"prefix":"10.1111","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8372-3754","authenticated-orcid":false,"given":"Akimichi","family":"Morita","sequence":"first","affiliation":[{"name":"Department of Geriatric and Environmental Dermatology Nagoya City University Graduate School of Medical Sciences Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7292-6732","authenticated-orcid":false,"given":"Fumikazu","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Department of Dermatology Kansai Medical University Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Matsuyama","sequence":"additional","affiliation":[{"name":"Department of Dermatology Tokai University Hachioji Hospital Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenzo","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of the Ryukyus Okinawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Arai","sequence":"additional","affiliation":[{"name":"St Luke's International Hospital Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6127-3182","authenticated-orcid":false,"given":"Akihiko","family":"Asahina","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Jikei University School of Medicine Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Imafuku","sequence":"additional","affiliation":[{"name":"Department of Dermatology Fukuoka University Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidemi","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Jikei University School of Medicine Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"AbbVie G.K. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Williams","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Matsuda","sequence":"additional","affiliation":[{"name":"AbbVie G.K. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6823-532X","authenticated-orcid":false,"given":"Susumu","family":"Kitamura","sequence":"additional","affiliation":[{"name":"AbbVie G.K. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,10,10]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.burns.2014.01.003"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14105"},{"key":"e_1_2_7_4_1","first-page":"2211","article-title":"Practice guidelines 2014 for generalized pustular psoriasis (GPP) [in Japanese]","volume":"125","author":"Terui T","year":"2015","journal-title":"Jpn J Dermatol"},{"key":"e_1_2_7_5_1","unstructured":"Eli Lilly Japan KK Torii Pharmaceutical Co. Ltd.Eli Lilly Japan and Torii Pharmaceutical launch \u201cTaltz\u00aeSubcutaneous Injection 80\u00a0mg Auto\u2010injector\u201d and \u201cTaltz\u00aeSubcutaneous Injection 80\u00a0mg Syringe\u201d humanized anti\u2010human IL\u201017A monoclonal antibody product. [Cited January 25 2018]. Available from:https:\/\/www.torii.co.jp\/en\/release\/."},{"key":"e_1_2_7_6_1","unstructured":"Kyowa Hakko Kirin Co. Ltd.LUMICEF\u00aeapproved in Japan. [Cited January 25 2018]. Available from:http:\/\/www.kyowa-kirin.com\/news_releases\/."},{"key":"e_1_2_7_7_1","unstructured":"Novartis.Novartis receives approval in the EU for Cosentyx label update includes long term superiority data versus Stelara in psoriasis. [Cited January 25 2018]. Available from:https:\/\/www.novartis.com\/news."},{"key":"e_1_2_7_8_1","unstructured":"Mitsubishi Tanabe Pharma.Approval for additional indication of psoriasis for Remicade\u00aeI.V. Drip Infusion 100 anti\u2010human TNF\u2010\u03b1 monoclonal antibody. [Cited January 19 2018]. Available from:https:\/\/www.mt-pharma.co.jp\/e\/release\/index.php?yearselect=2010."},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2009.00748.x"},{"key":"e_1_2_7_10_1","unstructured":"Remicade\u00ae(infliximab).Full Prescribing Information Janssen Biotech Inc. Horsham PA 2013."},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546630500430604"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.02972.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546630701759587"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13409"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199206000-00002"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/jech.53.1.46"},{"key":"e_1_2_7_18_1","volume-title":"Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels","author":"The Criteria Committee of the New York Heart Association","year":"1994"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13001"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13306"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2010.00971.x"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13698"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14702"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13622"},{"key":"e_1_2_7_25_1","unstructured":"Humira (adalimumab).Full Prescribing Information AbbVie G.K. Tokyo Japan http:\/\/www.abbvie.co.jp\/info-for-hcps\/info-about-our-products\/info-humira.html 2016."}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1346-8138.14664","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.14664","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T22:18:10Z","timestamp":1694729890000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.14664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,10]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1111\/1346-8138.14664"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.14664","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,10]]},"assertion":[{"value":"2018-05-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}